<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04773977</url>
  </required_header>
  <id_info>
    <org_study_id>CIBI362B102</org_study_id>
    <nct_id>NCT04773977</nct_id>
  </id_info>
  <brief_title>Clinical Study of IBI362 in Healthy Chinese Male Subjects</brief_title>
  <official_title>Clinical Study to Evaluate the Pharmacokinetics and Safety of IBI362 Lyophilized Powder and IBI362 Liquid Formulation in Healthy Chinese Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Innovent Biologics (Suzhou) Co. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Innovent Biologics (Suzhou) Co. Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study to evaluate the pharmacokinetic characteristics and safety of IBI362&#xD;
      lyophilized powder and IBI362 liquid formulation in healthy Chinese male subjects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pharmacokinetic；Safety&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 3, 2021</start_date>
  <completion_date type="Actual">June 17, 2021</completion_date>
  <primary_completion_date type="Actual">March 9, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate the PK parameters of IBI362 in healthy Chinese male subjects</measure>
    <time_frame>From the first dose of study drug until 8 weeks</time_frame>
    <description>Peak Plasma Concentration (Cmax)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluate the PK parameters of IBI362 in healthy Chinese male subjects</measure>
    <time_frame>From the first dose of study drug until 8 weeks</time_frame>
    <description>Area under the plasma concentration versus time curve (AUC)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events</measure>
    <time_frame>From the first dose of study drug until 8 weeks</time_frame>
    <description>The relationship of each adverse event to the investigational product was assessed by the investigator.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Overweight/Obesity</condition>
  <arm_group>
    <arm_group_label>IBI362 liquid formulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received single subcutaneous injection of IBI362 liquid formulation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IBI362 lyophilized powder</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received single subcutaneous injection of IBI362 lyophilized powder</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IBI362 liquid formulation</intervention_name>
    <description>Administered by subcutaneous injection</description>
    <arm_group_label>IBI362 liquid formulation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IBI362 lyophilized powder</intervention_name>
    <description>Administered by subcutaneous injection</description>
    <arm_group_label>IBI362 lyophilized powder</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. 20 years old≤ Healthy males≤45 years old&#xD;
&#xD;
          2. 19 kilograms per meter squared (kg/m²)≤Body Mass Index≤26 kg/m²&#xD;
&#xD;
          3. Willing and agreeable to commit to the duration of the study and undergo study&#xD;
             procedures as instructed by the clinic staff&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects who have previously completed or discontinued from this study, or who have&#xD;
             used IBI362.&#xD;
&#xD;
          2. Abnormal vital signs and physical examination during the screening period;&#xD;
&#xD;
          3. Having cardiovascular, respiratory, liver, kidney, digestive, endocrine, hematologic,&#xD;
             neurological, or muscle degenerative diseases can significantly affect drug&#xD;
             absorption, metabolism, or elimination, or participation in the study increases risk&#xD;
             or interferes with data interpretation.&#xD;
&#xD;
          4. Have a previous or current mental illness.&#xD;
&#xD;
          5. A family history of medullary thyroid carcinoma or multiple endocrine tumor syndrome&#xD;
             type 2.&#xD;
&#xD;
          6. There are other factors judged by the investigators that are not suitable for&#xD;
             inclusion in this study.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jian Li</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Sceond Affiliated Hospital of Nanchang University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Sceond Affiliated Hospital of Nanchang University</name>
      <address>
        <city>Nanchang</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>February 21, 2021</study_first_submitted>
  <study_first_submitted_qc>February 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 26, 2021</study_first_posted>
  <last_update_submitted>July 7, 2021</last_update_submitted>
  <last_update_submitted_qc>July 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pharmacokinetic</keyword>
  <keyword>Safety</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Overweight</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

